The open question is, again, what will be the percentage of such cases.
I don't doubt that reinfection will be rare, at least over the span of a few months, but to my mind that would seem unproven given how hard we're (generally) working to keep people from being infected in the first place.
'Quite high' could mean anything, but if you're implying 'higher than' then that isn't supported by the statistics I've seen in a dozen countries.
No. From the current papers, we just know that the reinfection where people have had their virus sequenced in both first and second infection is very rare.
The problem is technological. Up to now there are around 50 million confirmed cases in the world but probably less than 100 thousand sequencings performed, and only a few sequencings by those who had strong enough symptoms twice and had the chance to have sequencing twice.
Without sequencing one just can’t prove that some case is an actual reinfection. All other cases are just “possible” (i.e. unprovable) reinfections and nobody can claim anything worthy of a scientific paper about them.
But which of those will be by majority the study just didn’t investigate.
In immunology no answer is “yes” or “no” but the range. The range is different between different people, and we can conclude what the typical ranges are, if there’s enough data collected. But the ranges are still unknown at the moment.
The same reason (a need to find the ranges) is why you can’t make a vaccine candidate and be sure how it will work, unless you run big and long enough trials. And that’s why that takes time.
Here’s what this study figured out, quoting from the article: “The size of T cell response differed between individuals, being considerably (50%) higher in people who had experienced symptomatic disease at the time of infection six months previously. Further research will be needed to determine the significance of this finding.”
As you see, again some range, but also not concluding what you claim.